Robert Löfberg
About
In The Last Decade
Robert Löfberg
134 papers receiving 7.7k citations
Hit Papers
Peers
Comparison fields: 5 of 123
- Genetics 5.7k
- Epidemiology 4.4k
- Surgery 2.6k
- Oncology 1.5k
- Immunology 945
Countries citing papers authored by Robert Löfberg
This map shows the geographic impact of Robert Löfberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Löfberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Löfberg more than expected).
Fields of papers citing papers by Robert Löfberg
This network shows the impact of papers produced by Robert Löfberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Löfberg. The network helps show where Robert Löfberg may publish in the future.
Co-authorship network of co-authors of Robert Löfberg
This figure shows the co-authorship network connecting the top 25 collaborators of Robert Löfberg. A scholar is included among the top collaborators of Robert Löfberg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert Löfberg. Robert Löfberg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | 52 | |
| 3 | 195 | |
| 4 | Modern läkemedelsterapi vid Crohn - nationella riktlinjer. | 1 |
| 5 | 153 | |
| 6 | Effects of natalizumab on gut healing in a phase 3 study of active Crohn's disease therapy (ENACT-1) | 9 |
| 7 | Natalizumab decreases inflammatory cells within the colonic lamina propria of patients with active Crohn's disease: results from ENACT-1 | 3 |
| 8 | Grading system for inflammation in ulcerative colitis. Reply | 0 |
| 9 | 113 | |
| 10 | 209 | |
| 11 | 168 | |
| 12 | Colorectal cancer in colonic Crohn's disease-High frequency of DNA-aneuploidy | 1 |
| 13 | 157 | |
| 14 | 8 | |
| 15 | 124 | |
| 16 | [Great risk of cancer in ulcerative colitis. Colonoscopic monitoring is recommended]. | 3 |
| 17 | 56 | |
| 18 | Studies in longstanding ulcerative colitis with special reference to malignant transformation of the colorectal mucosa. | 4 |
| 19 | 61 | |
| 20 | 112 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.